IBI3034 has the potential to become a best-in-class molecule with its advantages in depth of response, longer dosing interval and better convenience. The IND-enabling study of IBI3034 is ongoing for a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback